檢索結果 - Samit Hirawat

  • Showing 1 - 9 results of 9
Refine Results
  1. 1
    PTC124 is an orally bioavailable compound that promotes suppression of the human <i>CFTR</i> -G542X nonsense allele in a CF mouse model

    PTC124 is an orally bioavailable compound that promotes suppression of the human <i>CFTR</i> -G542X nonsense allele in a CF mouse model 由 Ming Du, Xiaoli Liu, Ellen Welch, Samit Hirawat, Stuart W. Peltz, David M. Bedwell

    出版 2008
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    PI3K inhibitors as new cancer therapeutics: implications for clinical trial design

    PI3K inhibitors as new cancer therapeutics: implications for clinical trial design 由 Cristian Massacesi, Emmanuelle di Tomaso, Patrick Urban, Caroline Germa, Cornelia Quadt, Lucia Trandafir, Paola Aimone, Nathalie Fretault, Bharani Dharan, Ranjana Tavorath, Samit Hirawat

    出版 2016
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

    Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT 由 Neil A. O’Brien, K McDonald, Tong Luo, Erika von Euw, Ondrej Kalous, Dylan Conklin, Sara A. Hurvitz, Emmanuelle di Tomaso, Christian Schnell, Ronald Linnartz, Richard S. Finn, Samit Hirawat, Dennis J. Slamon

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy

    Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy 由 Cristina Saura, Johanna C. Bendell, Guy Jérusalem, Shaun Su, Qinhua Ru, Stefan Buck, David Mills, Sophie Ruquet, Ana Bosch, Ander Urruticoechea, J. Thaddeus Beck, Emmanuelle di Tomaso, David Sternberg, Cristian Massacesi, Samit Hirawat, Luc Dirix, José Baselga

    出版 2014
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  5. 5
    Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis

    Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis 由 Michael Wilschanski, L.L. Miller, David Shoseyov, H. Blau, Joseph Rivlin, Micha Aviram, Michael Cohen, S. Armoni, Yasmin Yaakov, T. Pugatch, Malena Cohen‐Cymberknoh, N.L. Miller, A. Reha, Valerie Northcutt, Samit Hirawat, K. Donnelly, Gary Elfring, Temitayo Ajayi, Eitan Kerem

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

    Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer 由 Neil A. O’Brien, Martina S.J. McDermott, Dylan Conklin, Tong Luo, Raul Ayala, Suruchi Salgar, Kevin Chau, Emmanuelle DiTomaso, Naveen Babbar, Faye Su, Alex Gaither, Sara A. Hurvitz, Ronald Linnartz, Kristine Rose, Samit Hirawat, Dennis J. Slamon

    出版 2020
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

    Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial 由 Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, A.-S. Longin, David Mills, C. Wilke, Samit Hirawat, Dejan Juric

    出版 2018
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Alpelisib for <i>PIK3CA</i>-Mutated, Hormone Receptor–Positive Advanced Breast Cancer 由 Fabrice André, Eva Ciruelos, Gábor Rubovszky, Mario Campone, Sibylle Loibl, Hope S. Rugo, Hiroji Iwata, Pierfranco Conté, Ingrid A. Mayer, Bella Kaufman, Toshinari Yamashita, Yen‐Shen Lu, Kenichi Inoue, Masato Takahashi, Zsuzsanna Pápai, Anne-Sophie Longin, David Mills, Celine Wilke, Samit Hirawat, Dejan Juric

    出版 2019
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer 由 Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch‐Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, Pierfranco Conté, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: